NEW YORK, April 1, 2008 (PRIME NEWSWIRE) -- Veteran business journalist Sasha Salama joins Richard G. Donnelly, President, Chief Executive Officer and Director, Aspen Bio Pharma, Inc. (Nasdaq:APPY) to discuss the company's industry, strategy, financials and positioning.
Click here to view video: http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=30535&k=F3719522FD31AC9E0255325F27695F63
Richard G. Donnelly was elected President, Chief Executive Officer and as a director, in January 2005. From September 1999 to December 2004, Mr. Donnelly served in senior marketing positions with Heska Corporation, including most recently as Senior Director of Marketing. From January 1993 to September 1999, Mr. Donnelly served as Director of Marketing for the Fort Dodge division of Wyeth Inc., (American Home Products). Mr. Donnelly holds a three-year diploma in Animal Science from St. Lawrence College
About Aspen Bio Pharma, Inc.
Aspen Bio Pharma, Inc. (the "Company" or "AspenBio" also we, us or our) is an emerging medical biotechnology company engaged in the discovery, research, development, manufacture, and licensing or marketing of novel drugs and diagnostics for human and animal healthcare. Founded in August 2000, as a Colorado corporation and headquartered in Castle Rock, Colorado, we leverage our proprietary knowledge and technology towards the development of novel patented or patentable products we believe have substantial market potential. Using our proprietary protein purifying methods and other proteomic technologies, we discovered several blood markers that appear to correlate with appendicitis in humans. We are currently engaged in the development and testing of our two first-generation blood-based human diagnostic tests designed to rapidly help screen or rule out appendicitis in patients complaining of abdominal pain. We are in the process of completing the appropriate requirements to file and secure a United States Food and Drug Administration ("FDA") 510(k) clearance for our initial screening technology, AppyScore, which in late 2007 demonstrated 98% sensitivity in a 471 patient multi-hospital study.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo can be found at http://www.primenewswire.com/newsroom/prs/?pkgid=4839